Peptide-based radiopharmaceuticals and cytotoxic conjugates: Potential tools against cancer
Author:
- 1 February 2008
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 34 (1) , 13-26
Abstract
No abstract availableKeywords
This publication has 72 references indexed in Scilit:
- Radiolabeled somatostatin receptor antagonists are preferable to agonists forin vivopeptide receptor targeting of tumorsProceedings of the National Academy of Sciences, 2006
- Imaging of Neuroendocrine TumorsSeminars in Nuclear Medicine, 2006
- Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analoguesEndocrine-Related Cancer, 2005
- Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypesNuclear Medicine and Biology, 2005
- Targeted therapy with a cytotoxic somatostatin analog, AN‐238, inhibits growth of human experimental endometrial carcinomas expressing multidrug resistance protein MDR‐1Cancer, 2005
- Growth inhibition of experimental non‐Hodgkin's lymphomas with the targeted cytotoxic somatostatin analogue AN‐238International Journal of Cancer, 2005
- First 18F-Labeled Tracer Suitable for Routine Clinical Imaging of sst Receptor-Expressing Tumors Using Positron Emission TomographyClinical Cancer Research, 2004
- Two Technetium-99m-Labeled Cholecystokinin-8 (CCK8) Peptides for Scintigraphic Imaging of CCK ReceptorsBioconjugate Chemistry, 2004
- Gastrin-Releasing Peptide (GRP) Analogues for Cancer ImagingCancer Biotherapy and Radiopharmaceuticals, 2004
- Highly Potent Cyclic Disulfide Antagonists of SomatostatinJournal of Medicinal Chemistry, 1999